June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
Nabhan, C.

PF381 FACTORS IMPACTING TREATMENT SELECTION IN TREATMENT-NAÏVE PATIENTS WITH CLL: A MULTICENTER STUDY

Rhodes, J.; Sail, K.; Sarraf Yazdy, M.; More

HemaSphere. 3(S1):142, June 2019.

Author:
Nabil, N.
Author:
Nadal, N.

PB1868 B-CELL PROLYMPHOCYTIC LEUKEMIA (B-PLL) AND PROLYMPHOCYTOID MANTLE CELL LYMPHOMA (PMCL) (MORE THAN 55% OF PROLYMPHOCYTES) ARE CLOSED BUT DISTINCT ENTITIES. ON BEHALF GFCH AND FILO GROUPS

Chapiro, E.; Diop, K.; Dessen, P.; More

HemaSphere. 3(S1):851-852, June 2019.

S1626 INCOMPLETE COUNT RECOVERY IN PATIENTS WITH COMPLETE REMISSION PRIOR TO ALLOGENEIC HCT FOR AML IS ASSOCIATED WITH A HIGH NON-RELAPSE MORTALITY WITHOUT AN INCREASED RELAPSE RISK

Innes, A.; Wooley, P.; Szydlo, R.; More

HemaSphere. 3(S1):751-752, June 2019.

Author:
Nadali, G.

PS1267 ISAVUCONAZOLE IN HEMATOLOGICAL PATIENTS: FINAL RESULTS OF A REAL-LIFE MULTICENTER SEIFEM (SORVEGLIANZA EPIDEMIOLOGICA DELLE INFEZIONI NELLE EMOPATIE) STUDY

Cattaneo, C.; Gramegna, D.; Busca, A.; More

HemaSphere. 3(S1):580-581, June 2019.

PS1276 EPIDEMIOLOGY AND CLINICAL OUTCOME OF FUNGAL INFECTIONS OF THE CENTRAL NERVOUS SYSTEM IN ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS

Facchin, G.; Candoni, A.; Busca, A.; More

HemaSphere. 3(S1):584, June 2019.

Author:
Nadarajah, N.

PF532 INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3(S1):218-219, June 2019.

Author:
Nadeu, F.

PF522 MUTATIONAL LANDSCAPE OF PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL) BY MEANS OF CIRCULATING TUMOR DNA ANALYSIS

Rivas-Delgado, A.; Nadeu, F.; Enjuanes, A.; More

HemaSphere. 3(S1):213-214, June 2019.

S843 THE PROLIFERATIVE HISTORY SHAPES THE DNA METHYLOME OF B-CELL TUMORS AND PREDICTS CLINICAL OUTCOME

Duran-Ferrer, M.; Clot, G.; Nadeu, F.; More

HemaSphere. 3(S1):376, June 2019.

Author:
Nadine, R.

PS1001 HACE1, A NOVEL TUMOR SUPPRESSOR GENE WHICH REGULATE THE RESPONSE OF VENETOCLAX, GANT61 AND NECROPTOSIS ACTIVATORS BY CONTROLLING C-FLIP, GLI2 AND BCL2 GENES IN ACUTE MYELOID LEUKEMIA

Garitano, A.; Teufel, E.; Kreckel, J.; More

HemaSphere. 3(S1):450, June 2019.

Author:
Nador, G.

PF599 EFFICACY OF BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH CARFILZOMIB-REFRACTORY MYELOMA IN THE UK NCRI CARDAMON TRIAL

Phillips, E.; Wilson, W.; Benjamin, R.; More

HemaSphere. 3(S1):252-253, June 2019.

Author:
Nagae, G.

PF532 INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3(S1):218-219, June 2019.

Author:
Nagai, H.

PF301 REDUCED-INTENSITY IMMUNOCHEMOTHERAPY WITHOUT VINCRISTINE IN ELDERLY PATIENTS OLDER THAN 80 YEARS OLD WITH DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTRE, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL

Yoshida, I.; Suehiro, Y.; Hirabayashi, Y.; More

HemaSphere. 3(S1):102-103, June 2019.

PS1259 LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA

Ogura, M.; Yamamoto, K.; Morishima, Y.; More

HemaSphere. 3(S1):575-576, June 2019.

S118 IMPACT OF PRE-TRANSPLANT DONOR-SPECIFIC ANTI-HLA ANTIBODIES IN CORD BLOOD TRANSPLANTATION ON BEHALF OF THE TRANSPLANT COMPLICATIONS WORKING GROUP OF JSHCT

Fuji, S.; Oshima, K.; Ohashi, K.; More

HemaSphere. 3(S1):11, June 2019.

Author:
Nagao, S.

PS1435 SLAMF7 HIGH CD16 NEGATIVE MONOCYTES INCREASE IN PERIPHERAL BLOOD OF PATIENTS WITH MYELOFIBROSIS IN CORRELATION WITH JAK2V617F MUTATION

Kato, S.; Maekawa, T.; Ogata, K.; More

HemaSphere. 3(S1):661-662, June 2019.

PF271 USING NEXT-GENERATION SEQUENCING TO PREDICT RESPONSE TO SALVAGE CHEMOTHERAPY WITH HIGH DOSE CYTARABINE AND MITOXANTRONE IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS

Canaani, J.; Nagar-Marciano, M.; Shimoni, A.; More

HemaSphere. 3(S1):87, June 2019.

Author:
Nagashima, T.

PF184 EFFICACY OF CONSOLIDATION CHEMOTHERAPY FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO ACHIEVED COMPLETE REMISSION BY FIRST COURSE OF REMISSION INDUCTION THERAPY

Shigematsu, A.; Ota, S.; Kobayashi, R.; More

HemaSphere. 3(S1):44, June 2019.

Author:
Nagata, H.
Author:
Nagata, Y.

PF532 INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3(S1):218-219, June 2019.

Author:
Nagate, Y.
Author:
Naggy, N.
Author:
Nagler, A.

S114 POST-TRANSPLANT CYCLOPHOSPHAMIDE VS ATG FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN T-REPLETE HAPLOIDENTICAL TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT OF THE ALWP/EBMT

Nagler, A.; Labopin, M.; Ruggeri, A.; More

HemaSphere. 3(S1):9, June 2019.

S115 IMPACT OF MESURABLE RESIDUAL DISEASE POSITIVITY ON OUTCOMES FOLLOWING UNMBILICAL CORD BLOOD TRANSPLANTATION: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT AND EUROCORD

Baron, F.; Labopin, M.; Ruggeri, A.; More

HemaSphere. 3(S1):9-10, June 2019.

PF271 USING NEXT-GENERATION SEQUENCING TO PREDICT RESPONSE TO SALVAGE CHEMOTHERAPY WITH HIGH DOSE CYTARABINE AND MITOXANTRONE IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS

Canaani, J.; Nagar-Marciano, M.; Shimoni, A.; More

HemaSphere. 3(S1):87, June 2019.

PF562 BLOCKING OF WIP1 PHOSPHATASE OVERCOMES BORTEZOMIB RESISTANCE AND PROMOTES CELL DEATH VIA ER STRESS-INDUCED APOPTOTIC JNK/C-JUN SIGNALING: NOVEL THERAPEUTIC TARGET IN MULTIPLE MYELOMA

Beider, K.; Rosenberg, E.; Dimenshtein, V.; More

HemaSphere. 3(S1):233, June 2019.

PF602 OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS

Montefusco, V.; Gay, F.; Spada, S.; More

HemaSphere. 3(S1):254-255, June 2019.

Author:
Nagtegaal, T.
Author:
Nagy, B. Jr.
Author:
Nagy, E.
Author:
Nagy, G.
Author:
Nagy, N.

PS1247 EZH2 GAIN-OF-FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A PRELIMINARY ANALYSIS ON 590 PATIENTS

Bödör, C.; Batlevi, C.; Nagy, N.; More

HemaSphere. 3(S1):568-569, June 2019.

Author:
Nagy, Z.

PF296 UPDATE OF THE SINGLE-ARM PHASE II L-MIND STUDY OF MOR208 PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: HIGH OVERALL RESPONSE RATES IN PATIENT SUBGROUPS WITH POOR PROGNOSIS

Duell, J.; Maddocks, K.; González Barca, E.; More

HemaSphere. 3(S1):100, June 2019.

PF348 LONG TERM FOLLOW-UP OF PNH PATIENTS TREATED WITH THE SMART ANTI-HC5 ANTIBODY (SKY59/RO7112689) IN THE OPEN LABEL EXTENSION (OLE) OF THE COMPOSER TRIAL

Röth, A.; Nagy, Z.; Peffault de Latour, R.; More

HemaSphere. 3(S1):125-126, June 2019.

Author:
Nahi, H.

PF592 IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3(S1):248-249, June 2019.

PF603 FASTER & SUSTAINED IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PTS TREATED WITH DARATUMUMAB, LENALIDOMIDE & DEXAMETHASONE (D-RD) VS RD: MAIA

Perrot, A.; Facon, T.; Plesner, T.; More

HemaSphere. 3(S1):255, June 2019.

S823 RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA

Mateos, M.-V.; Nahi, H.; Legiec, W.; More

HemaSphere. 3(S1):364, June 2019.

Author:
Nahi, H.N.

S1602 CARFILZOMIB AND DEXAMETHASONE MAINTENANCE PROLONG TIME TO PROGRESSION: FOLLOWING SALVAGE ASCT IN MULTIPLE MYELOMA: A RANDOMIZED PHASE 2 TRIAL BY THE NORDIC MYELOMA STUDY GROUP

Gregersen, H.; Peceliunas, V.; Remes, K.; More

HemaSphere. 3(S1):737-738, June 2019.

Author:
Nai, A.
Author:
Nair, S.
Author:
Najim, Z.
Author:
Najjar, L.
Author:
Najjar, O.
Author:
Nakagawa, M.

PF532 INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3(S1):218-219, June 2019.

PS983 NOVEL MOLECULAR PATHOGENESIS AND THERAPEUTIC TARGET IN ACUTE ERYTHROID LEUKEMIA

Takeda, J.; Shih, L.-Y.; Yoshida, K.; More

HemaSphere. 3(S1):442, June 2019.

PS1367 COMPREHENSIVE GENETIC ANALYSIS OF MULTIPLE MYELOMA IN JAPAN

Kanamori, T.; Sanada, M.; Ri, M.; More

HemaSphere. 3(S1):624-625, June 2019.

PB2055 HIGH PREVALENCE OF NON-GERMINAL CENTER B-CELL PHENOTYPE WITH MYC OVEREXPRESSION IN JAPANESE PATIENTS WITH INTRAVASCULAR LARGE B-CELL LYMPHOMA

Takahashi, H.; Nakanishi, Y.; Miura, K.; More

HemaSphere. 3(S1):927, June 2019.

Author:
Nakagawa, M.M.
Author:
Nakai, R.
Author:
Nakajima, K.
Author:
Nakamae, H.

S118 IMPACT OF PRE-TRANSPLANT DONOR-SPECIFIC ANTI-HLA ANTIBODIES IN CORD BLOOD TRANSPLANTATION ON BEHALF OF THE TRANSPLANT COMPLICATIONS WORKING GROUP OF JSHCT

Fuji, S.; Oshima, K.; Ohashi, K.; More

HemaSphere. 3(S1):11, June 2019.

PF407 TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3(S1):155-156, June 2019.

Author:
Nakamae, M.
Author:
Nakamaki, T.

S135 NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3(S1):19-20, June 2019.

Author:
Nakamaru, K.
Author:
Nakamura, A.

PF756 DONOR UNC-93 HOMOLOG B1 GENETIC VARIATION PREDICTS SURVIVAL OUTCOMES AFTER UNRELATED BONE MARROW TRANSPLANTATION

Uchino, K.; Mizuno, S.; Horio, T.; More

HemaSphere. 3(S1):332, June 2019.

Author:
Nakamura, S.

PS1259 LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA

Ogura, M.; Yamamoto, K.; Morishima, Y.; More

HemaSphere. 3(S1):575-576, June 2019.

PS1263 CONSOLIDATION THERAPY USING 90Y-IBRITUMOMAB TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRIZ2012)

Tsujimura, H.; Miura, K.; Kanno, M.; More

HemaSphere. 3(S1):578, June 2019.

Author:
Nakane, T.
Author:
Nakanishi, T.